Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more

Recent & Breaking News (NDAQ:EQ)

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Business Wire September 20, 2023

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Business Wire August 30, 2023

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Business Wire August 9, 2023

Equillium Announces $7.5 Million Share Repurchase Program

Business Wire August 2, 2023

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Business Wire June 1, 2023

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Business Wire May 15, 2023

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

Business Wire May 11, 2023

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Business Wire April 24, 2023

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Business Wire March 23, 2023

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Business Wire March 22, 2023

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Business Wire February 17, 2023

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Business Wire February 7, 2023

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Business Wire January 13, 2023

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Business Wire December 23, 2022

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Business Wire December 16, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

PR Newswire December 14, 2022

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

PR Newswire December 13, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBCF, PFHD, EQ, MTCR

PR Newswire December 8, 2022

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

PR Newswire December 7, 2022

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Business Wire December 6, 2022